SC to get nearly $9 million in opioid settlement

Posted 2/4/21

SC AG Alan Wilson announced Thursday a $573 million settlement with McKinsey & Company for its role in “turbocharging” the opioid epidemic with Purdue Pharma

Wilson joined a coalition of …

This item is available in full to subscribers.

Please log in to continue

Log in

SC to get nearly $9 million in opioid settlement

Posted

SC AG Alan Wilson announced Thursday a $573 million settlement with McKinsey & Company for its role in “turbocharging” the opioid epidemic with Purdue Pharma
Wilson joined a coalition of attorneys general from 47 states, the District of Columbia and five U.S. territories in a $573 million settlement with one of the world’s largest consulting firms, McKinsey & Company, resolving investigations into the company’s role in working for opioid companies, helping those companies promote their drugs, and profiting from the opioid epidemic.
The settlement, after payment of costs, will be used to abate problems caused by opioids in the participating states. SC will receive almost $9 million from the multistate settlement, to be paid over five years with most of it coming in the first year. This is the first multi-state opioid settlement to result in substantial payment to the states to address the epidemic.
In addition to providing funds to address the crisis, the agreement calls for McKinsey to prepare tens of thousands of its internal documents detailing its work for Purdue Pharma and other opioid companies for public disclosure online. In addition, McKinsey agreed to adopt a strict document retention plan, continue its investigation into allegations that two of its partners tried to destroy documents in response to investigations of Purdue Pharma, implement a strict ethics code that all partners must agree to each year, and stop advising companies on potentially dangerous Schedule II and III narcotics. 
“The opioid epidemic isn’t isolated to just one company or even all the companies that make the drugs,” Wilson said. “What we found in our investigation was that a big reason for the spread of opioids was how they were marketed to doctors with no regard for patients’ health and safety. While opioids may be medically necessary, their marketing may also make them in many cases poison pills.​”
 Thursday’s filings describe how McKinsey contributed to the opioid crisis by promoting marketing schemes and consulting services to opioid manufacturers, including OxyContin maker Purdue Pharma, for over a decade. The complaint, filed with the settlement, details how McKinsey advised Purdue on how to maximize profits from its opioid products, including targeting high-volume opioid prescribers, using specific messaging to get physicians to prescribe more OxyContin to more patients, and circumventing pharmacy restrictions in order to deliver high-dose prescriptions.
When states began to sue Purdue’s directors for their implementation of McKinsey’s marketing schemes, McKinsey partners began emailing about deleting documents and emails related to their work for Purdue.
The opioid epidemic has led to considerable harm to individuals and communities in South Carolina over the last 20 years. During this time, thousands have died from an opioid overdose. On an economic level, these deaths—and the impacts on South Carolinians who have struggled with opioid addiction—have created considerable costs to SC in the form of health care, child welfare, criminal justice, and many other programs needed to lessen the epidemic. It has also resulted in lost economic opportunity and productivity. On the social level, opioid addiction, abuse, and overdose deaths have torn families apart, damaged relationships, and eroded the social fabric of communities. 
Wilson's Office is participating in a global settlement framework agreement involving the now bankrupt opioid manufacturer Mallinckrodt. On Aug. 15, 2019, the Attorney General filed a lawsuit against the three largest opioid distributors, Cardinal, McKesson, and AmerisourceBergen, alleging they violated the SC Unfair Trade Practices Act and created a public nuisance. The Attorney General previously filed suit on Aug. 15, 2017 against opioid manufacturer Purdue Pharma.
The states’ investigation was led by an executive committee made up of the attorneys general of California, Colorado, Connecticut, Massachusetts, New York, North Carolina, Oklahoma, Oregon, Tennessee, and Vermont. The executive committee is joined by the attorneys general of Alabama, Alaska, Arizona, Arkansas, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, New Hampshire, New Jersey, New Mexico, North Dakota, Ohio, Pennsylvania, Rhode Island, South Carolina, South Dakota, Texas, Utah, Virginia, Wisconsin, Wyoming, the District of Columbia, and the territories of American Samoa, Guam, the Northern Mariana Islands, Puerto Rico, and the U.S. Virgin Islands.

Comments

No comments on this item Please log in to comment by clicking here